H.C. Wainwright upgraded Iterum Therapeutics to Buy from Neutral with a $6 price target. The analyst believes sulopenem is likely to be approved by the FDA in Q4, or about six months after a new drug application resubmission currently expected in Q2. The firm says Iterum has now financial overhang while exploring partnership options.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ITRM:
- Biotech Alert: Searches spiking for these stocks today
- Iterum Shareholders Reject Board’s Share Issuance Proposal
- Iterum Therapeutics Announces Triumph in Phase 3 uUTI Trial
- Iterum Therapeutics Reports Positive Phase 3 Trial Results
- Iterum Therapeutics’ sulopenem shows positive results in urinary infections
